Nicotine Withdrawal Syndrome

Abstract

Smoking remains a global health problem that contributes significantly to morbidity and mortality. Although most smokers are aware of the harmful effects of smoking, many struggle to quit due to nicotine dependence and the development of nicotine withdrawal syndrome (NWS). This literature review aims to examine the mechanisms, clinical manifestations, and management approaches for NWS. Nicotine contained in tobacco products binds to nicotinic acetylcholine receptors (nAChRs) in the central nervous system and triggers the release of various neurotransmitters that play a role in the addiction process. Cessation or reduction of nicotine consumption after chronic use causes neurobiological changes such as upregulation and desensitization of nAChRs, disruption of the dopaminergic system, and involvement of the habenular complex, hippocampus, and amygdala, which underlie the onset of nicotine withdrawal symptoms. NWS symptoms typically appear within 4–24 hours after nicotine cessation, peak on the third day, and can last for several weeks. Clinical manifestations include affective symptoms such as anxiety, irritability, depression, and anhedonia; somatic symptoms such as increased appetite, gastrointestinal disturbances, and tremors; and cognitive impairment. and cognitive symptoms such as impaired concentration and memory. The level of nicotine dependence can be assessed using the Fagerström Nicotine Dependence Test. Treatment includes behavioral interventions and pharmacotherapy, such as nicotine replacement therapy, bupropion, and varenicline. The combination of behavioral and pharmacological therapy has been shown to increase smoking cessation success compared to either intervention alone. A better understanding of the mechanisms and management of NWS is expected to increase the success of smoking cessation programs and reduce the burden of tobacco-related diseases.